Omeros Corporation

NASDAQ:OMER

Biotechnology

Healthcare
$14.55 +4.46%

+$0.43 today

Market cap
$1.08B
Beta
2.53
P/E (TTM)
8.4
EPS (TTM)
$1.20
52W Low $2.95High $17.65

Volume 2.53M

Average 1.55M

OMER Debt Repayment

Cash used to repay borrowings during the period.

Omeros CorporationNASDAQ: OMER

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment growth accelerates

Q1 FY2026 debt repayment of $21.93M (cash outflow) rose 1053.0% year over year, ahead of the +187.6% change in trailing-twelve-month debt repayment. Sequentially, it fell 75.2% from the prior quarter.

Context

  • Debt repayment increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1053.0% holds above the trailing-twelve-month pace of +187.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$21.93M-75.2% QoQ
Last fiscal yearDec 2025
-$89.16M+115.7% YoY
LTMMar 2026
-$109.19M+187.6% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1053.0%——
1 year+115.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(89.16M) USD
Year-over-year change
-115.7%

Debt Repayment vs competitors

How OMER compares with its peers on the latest reported figures

  • OMER's LTM Mar 2026 debt repayment of $109.19M is the largest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of +187.6% is the highest of 3, against a peer median of +23.8%.
  • Debt repayment amounts to 1103.7% of revenue for OMER, versus a peer median of 0.0%.
OMER Competitors Peer median
Debt Repayment for OMER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OMEROmeros CorporationLTM Mar 2026$109.19M +187.6%—1103.7%
ANABAnaptysBio, Inc.LTM Mar 2026$66.6M +147.6%—28.7%
XNCRXencor, Inc.LTM Jun 2026$0 ——0.0%
RCUSArcus Biosciences, Inc.LTM Jun 2026$0 -100.0%—0.0%
BHVNBiohaven Ltd.LTM Jun 2026$0 —-17.7%—
NKTRNektar TherapeuticsLTM Jun 2026$0 ——0.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$0 ———
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$0 ———
CGENCompugen Ltd.LTM Dec 2025$0 ——0.0%
MGNXMacroGenics, Inc.LTM Mar 2026$0 ——0.0%
MREOMereo BioPharma Group plcLTM Mar 2026$0 ——0.0%
Peer median (excluding OMER) $0+23.8%-17.7%0.0%

Competitors are the stored peer set for OMER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(191.55M)(182.03M)(117.81M)(156.82M)(3.35M)
Depreciation & Amortization1.39M952K920K950K964K
Deferred Income Tax00000
Stock-Based Compensation0011.65M10.49M8.19M
Change in Working Capital(14.11M)(118.97M)247.42M29.74M33.72M
Accounts Receivables(34.31M)(175.07M)245.72M40.01M30.45M
Inventory00000
Accounts Payables14.64M(10.67M)000
Other Working Capital5.57M66.76M1.7M(10.27M)3.27M
Other Non-Cash Items94.54M213.56M(67.46M)(33.17M)(155.62M)
Operating Cash Flow(109.72M)(86.48M)74.73M(148.8M)(116.09M)
Capital Expenditures(277K)(113K)(426K)(165K)(65K)
Acquisitions (Net)125.99M0000
Purchases of Investments(32.01M)(429.05M)(1.02B)(987.39M)(185.31M)
Sales of Investments100M301.59M1.05B1.07B109.9M
Other Investing Activities0000240M
Investing Cash Flow193.71M(127.56M)27.45M82.22M164.52M
Debt Repayment(1.82M)123.83M(101.58M)(41.34M)(89.16M)
Common Stock Issued8.38M415K0046.99M
Common Stock Repurchased00(4.65M)(11.85M)0
Dividends Paid00000
Other Financing Activities(241K)0150K116.07M0
Financing Cash Flow6.32M124.25M(106.08M)62.88M(42.17M)
Effect of Forex Changes00000
Net Change in Cash90.31M(89.8M)(3.9M)(3.71M)6.26M
Free Cash Flow(110M)(86.6M)74.3M(148.97M)(116.16M)

Omeros Corporation

NASDAQ:OMER

Intrinsic Alpha fair value

Locked

Current Price

$14.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.